Cargando…

Fludarabine as a cost-effective adjuvant to enhance engraftment of human normal and malignant hematopoiesis in immunodeficient mice

There is still an unmet need for xenotransplantation models that efficiently recapitulate normal and malignant human hematopoiesis. Indeed, there are a number of strategies to generate humanized mice and specific protocols, including techniques to optimize the cytokine environment of recipient mice...

Descripción completa

Detalles Bibliográficos
Autores principales: Pievani, A., Michelozzi, I. M., Rambaldi, B., Granata, V., Corsi, A., Dazzi, F., Biondi, A., Serafini, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6002385/
https://www.ncbi.nlm.nih.gov/pubmed/29904072
http://dx.doi.org/10.1038/s41598-018-27425-x
_version_ 1783332191474810880
author Pievani, A.
Michelozzi, I. M.
Rambaldi, B.
Granata, V.
Corsi, A.
Dazzi, F.
Biondi, A.
Serafini, M.
author_facet Pievani, A.
Michelozzi, I. M.
Rambaldi, B.
Granata, V.
Corsi, A.
Dazzi, F.
Biondi, A.
Serafini, M.
author_sort Pievani, A.
collection PubMed
description There is still an unmet need for xenotransplantation models that efficiently recapitulate normal and malignant human hematopoiesis. Indeed, there are a number of strategies to generate humanized mice and specific protocols, including techniques to optimize the cytokine environment of recipient mice and drug alternatives or complementary to the standard conditioning regimens, that can be significantly modulated. Unfortunately, the high costs related to the use of sophisticated mouse models may limit the application of these models to studies that require an extensive experimental design. Here, using an affordable and convenient method, we demonstrate that the administration of fludarabine (Fludara(TM)) promotes the extensive and rapid engraftment of human normal hematopoiesis in immunodeficient mice. Quantification of human CD45(+) cells in bone marrow revealed approximately a 10(2)-fold increase in mice conditioned with irradiation plus fludarabine. Engrafted cells in the bone marrow included hematopoietic stem cells, as well as myeloid and lymphoid cells. Moreover, this model proved to be sufficient for robust reconstitution of malignant myeloid hematopoiesis, permitting primary acute myeloid leukemia cells to engraft as early as 8 weeks after the transplant. Overall, these results present a novel and affordable model for engraftment of human normal and malignant hematopoiesis in immunodeficient mice.
format Online
Article
Text
id pubmed-6002385
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-60023852018-06-26 Fludarabine as a cost-effective adjuvant to enhance engraftment of human normal and malignant hematopoiesis in immunodeficient mice Pievani, A. Michelozzi, I. M. Rambaldi, B. Granata, V. Corsi, A. Dazzi, F. Biondi, A. Serafini, M. Sci Rep Article There is still an unmet need for xenotransplantation models that efficiently recapitulate normal and malignant human hematopoiesis. Indeed, there are a number of strategies to generate humanized mice and specific protocols, including techniques to optimize the cytokine environment of recipient mice and drug alternatives or complementary to the standard conditioning regimens, that can be significantly modulated. Unfortunately, the high costs related to the use of sophisticated mouse models may limit the application of these models to studies that require an extensive experimental design. Here, using an affordable and convenient method, we demonstrate that the administration of fludarabine (Fludara(TM)) promotes the extensive and rapid engraftment of human normal hematopoiesis in immunodeficient mice. Quantification of human CD45(+) cells in bone marrow revealed approximately a 10(2)-fold increase in mice conditioned with irradiation plus fludarabine. Engrafted cells in the bone marrow included hematopoietic stem cells, as well as myeloid and lymphoid cells. Moreover, this model proved to be sufficient for robust reconstitution of malignant myeloid hematopoiesis, permitting primary acute myeloid leukemia cells to engraft as early as 8 weeks after the transplant. Overall, these results present a novel and affordable model for engraftment of human normal and malignant hematopoiesis in immunodeficient mice. Nature Publishing Group UK 2018-06-14 /pmc/articles/PMC6002385/ /pubmed/29904072 http://dx.doi.org/10.1038/s41598-018-27425-x Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Pievani, A.
Michelozzi, I. M.
Rambaldi, B.
Granata, V.
Corsi, A.
Dazzi, F.
Biondi, A.
Serafini, M.
Fludarabine as a cost-effective adjuvant to enhance engraftment of human normal and malignant hematopoiesis in immunodeficient mice
title Fludarabine as a cost-effective adjuvant to enhance engraftment of human normal and malignant hematopoiesis in immunodeficient mice
title_full Fludarabine as a cost-effective adjuvant to enhance engraftment of human normal and malignant hematopoiesis in immunodeficient mice
title_fullStr Fludarabine as a cost-effective adjuvant to enhance engraftment of human normal and malignant hematopoiesis in immunodeficient mice
title_full_unstemmed Fludarabine as a cost-effective adjuvant to enhance engraftment of human normal and malignant hematopoiesis in immunodeficient mice
title_short Fludarabine as a cost-effective adjuvant to enhance engraftment of human normal and malignant hematopoiesis in immunodeficient mice
title_sort fludarabine as a cost-effective adjuvant to enhance engraftment of human normal and malignant hematopoiesis in immunodeficient mice
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6002385/
https://www.ncbi.nlm.nih.gov/pubmed/29904072
http://dx.doi.org/10.1038/s41598-018-27425-x
work_keys_str_mv AT pievania fludarabineasacosteffectiveadjuvanttoenhanceengraftmentofhumannormalandmalignanthematopoiesisinimmunodeficientmice
AT michelozziim fludarabineasacosteffectiveadjuvanttoenhanceengraftmentofhumannormalandmalignanthematopoiesisinimmunodeficientmice
AT rambaldib fludarabineasacosteffectiveadjuvanttoenhanceengraftmentofhumannormalandmalignanthematopoiesisinimmunodeficientmice
AT granatav fludarabineasacosteffectiveadjuvanttoenhanceengraftmentofhumannormalandmalignanthematopoiesisinimmunodeficientmice
AT corsia fludarabineasacosteffectiveadjuvanttoenhanceengraftmentofhumannormalandmalignanthematopoiesisinimmunodeficientmice
AT dazzif fludarabineasacosteffectiveadjuvanttoenhanceengraftmentofhumannormalandmalignanthematopoiesisinimmunodeficientmice
AT biondia fludarabineasacosteffectiveadjuvanttoenhanceengraftmentofhumannormalandmalignanthematopoiesisinimmunodeficientmice
AT serafinim fludarabineasacosteffectiveadjuvanttoenhanceengraftmentofhumannormalandmalignanthematopoiesisinimmunodeficientmice